TrialCancer chemotherapy and pharmacology2016

A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib.

Vikram Malhi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.